Fiducial Markers Market By Product (Gold, Gold Combination, Polymer, Others) By Modality (CT/CBCT, MRI, Ultrasound, Radiotherapy) By Application (Prostate Cancer, Lung Cancer, Breast Cancer, Gastric Cancer, Other Cancers) End User (Hospitals & Outpatient Facilities, Independent Radiotherapy Centers, Cancer Research Centers) and Geography

 

Fiducial Markers Market size was valued at USD 112.4 million in 2021 and is expected to grow at a CAGR of 4.7% during the forecast period 2022 to 2028. The global market provides a detailed overview and that can be segmented by product, by modality, and by Application. By product, the Fiducial Markers market growth has been segmented into Gold, Gold Combination, Polymer, and Others. The Gold segment is likely to be the largest and fastest-growing segment in terms of product. The rise of this segment is mainly due to the superior stability and precise visibility of these products across numerous imaging sensory systems. Gold fiducial markers is also available in amalgamation with other metals, such as platinum, titanium, and nickel, for improved efficiency. For instance, when mixed with titanium stripes, these markers improve the visibility in MRI photos. Based on Modality, the Fiducial Markers market is segmented into CT/CBCT, MRI, Ultrasound, and Radiotherapy. Among these, the CT/CBCT segment is expected to have the fastest-growing market during the forecast period 2022-2028. Low dose exposure, the comfort of integration with current radiotherapy instruments, and orthogonal imaging characteristics of CBCT is the primary factors attributing to the fiducial markers market growth. Based on the Application, the Fiducial Markers market is segmented into Prostate Cancer, Lung Cancer, Breast Cancer, Gastric Cancer, and Other Cancers. The Prostate Cancer segment is expected to have a significant share in 2021. Rising product acceptance in the treatment of prostate cancer is the major factor driving the growth of the segment. The lung cancer segment is anticipated to observe the fastest growth. Based on the end user, the Fiducial Markers market is segmented into Hospitals & Outpatient Facilities, Independent Radiotherapy Centers, and Cancer Research Centers. The Hospitals & Outpatient Facilities segment is expected to have a significant share in 2021. Key Development: In February 2021, GE Healthcare announced innovative oncology care solutions In August 2022, ZOZO launched a zozofit 3D body measurement system to transform fit technology using the fiducial marker.